Page last updated: 2024-12-08

testololactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID160753
CHEBI ID18084
SCHEMBL ID1331106
MeSH IDM0069434

Synonyms (27)

Synonym
(4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,9,10,10a,10b,11,12,12a-dodecahydro-2h-naphtho[2,1-f]chromene-2,8(4bh)-dione
hydrotestolactone
3-oxo-13,17-secoandrost-4-eno-17,13alpha-lactone
CHEBI:18084
LMST02020061
d-homo-17a-oxaandrost-4-ene-3,17-dione
17a-oxa-d-homoandrost-4-ene-3,17-dione
testololactone ,
3-oxo-13,17-secoandrost-4-ene-17,13alpha-lactone
4416-57-3
C04676
d-homo-17alpha-oxaandrost-4-ene-3,17-dione
17alpha-oxo-d-homoandrost-4-ene-3,17-dione
(4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-4,4a,4b,5,6,9,10,10b,11,12-decahydro-3h-naphtho[2,1-f]chromene-2,8-dione
SCHEMBL1331106
3rql9ve1nb ,
unii-3rql9ve1nb
13,17-secoandrost-4-en-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
testolactone, 3
bdbm91714
2h-phenanthro(2,1-b)pyran-2,8(4bh)-dione, 3,4,4a,5,6,9,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-, (4as,4br,10ar,10bs,12as)-
(4as,4br,10ar,10bs,12as)-3,4,4a,5,6,9,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-2h-phenanthro(2,1-b)pyran-2,8(4bh)-dione
13,17-secoandrost-4-en-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
2h-phenanthro(2,1-b)pyran-2,8(4bh)-dione, 3,4,4a,5,6,9,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-, (4as-(4a.alpha.,4b.beta.,10a.beta.,10b.alpha.,12a.beta.))-
Q27102810
(4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-4,4a,4b,5,6,9,10,10a,10b,11,12,12a-dodecahydro-2h-naphtho[2,1-f]chromene-2,8(3h)-dione
13-hydroxy-3-oxo-13,17-secoandrost-4-en-17-oic acid delta-lactone

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" If correct, two clinically available aromatase inhibitors, aminoglutethimide (AG) and testololactone (TL) could potentially be given together at lower than usual dosage with reduction of patient side effects and preservation of aromatase inhibition."( Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase.
Osawa, Y; Rosen, H; Santen, RJ; Santner, SJ, 1984
)
0.76
" Long-term therapy (up to 6 months) with the 250-mg dosage showed continual suppression of estrone with no escape being observed."( In vivo effects of delta 1-testololactone on peripheral aromatization.
Barone, RM; Gambone, JC; Judd, HL; Lasley, BL; Laufer, LR; Monfort, SL, 1982
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
seco-androstane
steroid lactone
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)142.45000.00001.559910.0000AID1799735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1799735Cholinesterase Inhibition Assay from Article 10.1080/14756360802236393: \\Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.\\2009Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2
Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (80.65)18.7374
1990's0 (0.00)18.2507
2000's3 (9.68)29.6817
2010's3 (9.68)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.88%)5.53%
Reviews4 (11.76%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other27 (79.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]